Introduction
As a well-known F-box protein, S-phase kinase-associated protein 2 (Skp2) can function as a classic oncogene in cancer cell survival via inducing some factors' degradation. [1] [2] [3] [4] [5] [6] [7] A cascade composed of some F-box proteins including Skp2 has an effect on the cell growth of lung cancer. 8 Highly expressed Skp2 is associated with a poor prognosis, and promotes tumor development including metastasis and invasion in non-small cell lung cancer. [9] [10] [11] Skp2 suppression makes lung cancer cells sensitive to drugs. 12 Overexpressed Skp2 is able to depress the radiation-induced bystander effects in esophageal carcinoma. 13 Skp2 destabilizes Twist to regulate castration-resistant prostate cancer progression.
14 Skp2 is stabilized by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation in augmentation of gastric cancer. 15 Skp2 is involved in N-myc downstream regulated gene 1-regulated c-Myc degradation in the maintenance of lung cancer cell stem-like properties. 16 It has been reported that YAP can induce Skp2 acethylation through the AKT pathway to enhance tumorigenesis. 17 Skp2 can be post-transcriptionally regulated by Bcl-2-associated athanogene 3 in promotion of ovarian cancer cell proliferation. 18 MYC is capable of forming a bidirectional cross-talk with CDK2, p27, or Skp2 to accelerate tumor development. 19 Mechanical tensions-induced YAP promotes oncogenesis through Skp2 in breast cancer. 20 In colorectal cancer, some oncogenes including Skp2 together with microRNAs (miRNAs) and tumor suppressor genes form the co-regulatory networks. 21 Yet, the post-transcriptional regulation mechanism of Skp2 remains to be further investigated.
MiRNAs are capable of inhibiting transcription or translation of target genes. MiR-339 can serve as a tumor suppressor miRNA in many types of cancers. MiR-339 can suppress cell migration and invasion in breast cancer. 22 MiR-339 targeting PRL-1 is involved in the progression of colorectal cancer. 23 In non-small cell lung cancer, miR-339 is related to tumor metastasis staging. 24 MiR-339 is able to target MDM2 to affect the p53 pathway. 25 MiR-339 plays a great part in cell invasion in liver cancer. 26 A report has shown that miR-508 can target Skp2 to inhibit gastric cancer metastasis. 27 However, whether miR-339 is able to target Skp2 in lung cancer is unexplored.
We are interested in whether miR-339 has an effect on post-transcriptional regulation of Skp2 in lung cancer. We reveal that miR-339 restrains lung cancer proliferation through directly targeting Skp2 3 0 -untranslated region (3'UTR). We present a novel perspective for understanding how lung cancer development by Skp2 is modulated.
Methods

Cell line
Ten percent fetal bovine serum was added into Dulbecco's modified Eagle's medium (Gibco, Carlsbad, CA, USA) to culture human lung cancer cell line A549. Cells were contained in a 5% CO 2 incubator at 37 C. 
RNA isolation and real
Plasmids construction
Full-length Skp2 was amplified and cloned into pcDNA3.1 vector (primers: forward, 5
. Wild type (wt) or mutated (mut) miR-339 targeting site in Skp2 3'UTR was cloned into pGL3-control vector (primers: wt forward, 5
siRNAs, miRNA, and miRNA inhibitor transfection
Transient transfection of cells was performed using Lipofectamine 2000 (Invitrogen). MiR-339, control, inhibitor, and siSkp2 were synthesized by RiboBio (Guangzhou, China). siSkp2-1,
Luciferase reporter gene assays
Seeded cells on 24-well plates were cultured overnight. Lipofectamine 2000 (Invitrogen) was applied to transfect the indicated luciferase reporters and/or miRNA (inhibitor). Renilla luciferase activities were utilized to normalize Firefly luciferase activities. Luciferase activity was analyzed using Dual-Luciferase ® Reporter Assay System (Promega, Madison, WI, USA) and monitored by a luminometer (Promega).
Immunoblotting
Radioimmunoprecipitation assay buffer was used to isolate total protein. Cambridge, MA, USA) followed by the corresponding secondary antibody.
Proliferation assays
3-(4,5-Dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) and colony formation assays were used to evaluate cell proliferation ability. A549 cells seeding on 96-well plates at 1000 cells/well were transfected. After transfection, cell proliferation was evaluated by MTT assay once per day for three days. For colony formation analysis, post-forty-eight hours after transfection with miR-339, miR-339 + Skp2, anti-miR-339, anti-miR-339 + siSkp2-1, or negative control seeded cells on six-well plates (1000 cells/well) were cultured for two weeks until visible colonies formed. The colonies were fixed with 4% paraformaldehyde and stained with methylene blue. Colonies were counted by three observers separately.
Patient samples
The Sir Run Run Shaw Hospital (Hangzhou, China) provided 32 lung cancer tissues harvested from lung cancer patients by surgery (Table S1 ). Written consent was banked with tissues, and the study protocol has been approved by the Research Ethics Board.
Statistical analysis
Every experiment was performed in triplicate. Data were recorded as mean AE SD. Student's t-test was utilized to compare different groups' differences. A P-value <0.05 was determined significant. The correlation between miR-339 and Skp2 in lung cancer samples was evaluated by Pearson's correlation coefficient.
Results
Low level of miR-339 is related to highly expressed Skp2 in clinical lung cancer tissues Skp2 abundance is frequently found in multiple cancers. A high level of Skp2 is involved in the development of many cancers. Tumor suppressor, miR-339, has an effect on the progression of many cancers. To explore the relationship of miR-339 and Skp2 in lung cancer development, we examined the expression of miR-339 and Skp2 in 32 clinical lung cancer samples. Our data showed that a low level of miR-339 was related to a high level of Skp2 in clinical lung cancer samples (Pearson's correlation coefficient of −0.7982, P < 0.001) (Fig 1a) . In addition, Skp2 expression was confirmed in lung cancer samples by real time-PCR assay. Abundant Skp2 expression in lung cancer tissues was observed (Fig 1b) . Our data hint that deregulated miR-339 is related to upregulated Skp2 in clinical lung cancer tissues.
MiR-339 is able to control Skp2 expression in lung cancer cells
Then, we tried to evaluate the effect of miR-339 on Skp2 expression lung cancer cells. We examined the Skp2 level in miR-339 or anti-miR-339-treated cells using real time-PCR and immunoblotting. As shown in Figure 2a , miR-339 decreased the mRNA and protein levels of Skp2. Furthermore, the expression of Skp2 was elevated in miR-339-depleted cells (Fig 2b) . Our data imply that miR-339 is able to control Skp2 expression in lung cancer. Meanwhile, miR-339 and anti-miR-339 transfection was evaluated by real time-PCR (Fig 2a,b) . Collectively, our data support that miR-339 is capable of depressing Skp2 in lung cancer cells. 
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MiR-339 directly targets Skp2 3 0 UTR to inhibit its expression Next, we wanted to investigate the Skp2 post-transcriptional regulation in lung cancer. MiRNA.org was applied to predict the miRNAs that could target Skp2. MiR-339 was a potential regulatory miRNA of Skp2. To test the effect of miR-339 on Skp2, we cloned the wild-type (wt) or mutant (mut) 3 0 UTR of Skp2 into pGL3-control plasmid (pGL3-Skp2-wt and pGL3-Skp2-mut) (Fig 3a) . The pGL3-Skp2-wt or pGL3-Skp2-mut plasmid combined with miR-339 or inhibitor (anti-miR-339) was transfected into A549 cells. We found that ectopic miR-339 expression significantly decreased the luciferase activities of pGL3-Skp2-wt in lung cancer A549 cells. However, miR-339 lost the inhibitory effect on pGL3-Skp2-mut containing the seed region mutation in cells The effect of miR-339 or inhibitor (anti-miR-339) on pGL3-Skp2-wt or pGL3-Skp2-mut was analyzed by luciferase reporter gene analysis in A549 cells. ***P < 0.01; **P < 0.01; NS, not significant; Student's t-test.
Thoracic Cancer 9 (2018) 408-414 (Fig 3b) . In addition, miR-339 inhibitor (anti-miR-339) was capable of decreasing the miR-339 level to enhance the luciferase activities of the pGL3-Skp2-wt. Nevertheless, pGL3-Skp2-mut cannot be affected by anti-miR-339 introduction (Fig 3c) . Our data indicate that miR-339 inhibits Skp2 expression via directly targeting its mRNA 3 0 UTR in lung cancer cells.
MiR-339 targeting Skp2 contributes to cell proliferation inhibition in lung cancer
To further evaluate the function of miR-339 targeting Skp2 in lung cancer, we performed MTT and colony formation analysis. We first evaluated the effect of two different siRNAs targeting Skp2 on the expression of Skp2 (Fig 4a) . Then, we found that the miR-339-overexpressed cells showed more highly proliferative ability, while ectopic Skp2 expression was able to recover the miR-339-suppressed cell proliferation. Furthermore, anti-miR-339 transfection showed the inhibitory effect on cell proliferation, but Skp2 siRNA could breach the acceleration of cell proliferation induced by anti-miR-339 (Fig 4b) . Taken a further step, colony formation assay showed that the colony numbers were less in miR-339-treated cells compared with that in the control group. Anti-miR-339 was able to enhance the colony formation in the cells. Notably, Skp2 siRNA could destroy the anti-miR-339-augmented colony formation in A549 cells (Fig 4c) . Our data support that miR-339 can bate Skp2 to restrain cell proliferation in lung cancer.
Discussion
Lung cancer is the leading cause of cancer-related death and the most prevalent malignancy in the world. Skp2 is a classic oncogene during the development of cancers 
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Thoracic Cancer 9 (2018) 408-414involving some factors' degradation. [1] [2] [3] [4] [5] [6] [7] Highly expressed Skp2 can serve as a poor prognosis marker in non-small cell lung cancer. [9] [10] [11] The progression of castration-resistant prostate cancer is modulated by Skp2 via destabilizing Twist.
14 Lung cancer cells become sensitive to drugs for Skp2 inhibition. 12 Bcl-2 associated athanogene 3 can posttranscriptionally modulate Skp2 in ovarian cancer growth. 18 However, the post-transcriptional regulation mechanism of Skp2 remains unexplored.
Previous studies have shown that miR-339 plays key roles as a tumor suppressor miRNA in many types of cancers. In breast cancer, miR-339 has an inhibitory effect on cell migration and invasion. 22 MiR-339 targeting PRL-1 partakes in colorectal cancer progression. 23 Non-small cell lung cancer metastasis staging is related to miR-339 level. 24 MiR-339 plays a great part in cell invasion in liver cancer. 26 We first evaluated the negative correlation between miR-339 and Skp2 in clinical lung cancer tissues. Furthermore, our data showed that the level of Skp2 could be decreased by miR-339 using real time-PCR and immunoblotting, further indicating that miR-339 is able to target Skp2. To investigate how miR-339 regulates Skp2 in lung cancer, we predicted which miRNA might target Skp2 by microRNA.org analysis. MiR-339 was a potential regulatory miRNA of Skp2 for its tumor suppressor role in multiple cancers. However, whether miR-339 is able to target Skp2 to regulate its expression in lung cancer remains unclear. To further clarify the regulation of miR-339 on Skp2, we cloned the wild-type (wt) and mutant (mut) 3 0 UTR of Skp2 into pGL3-control plasmid. We showed that ectopic miR-339 expression significantly decreased the luciferase activity of pGL3-Skp2-wt in lung cancer A549 cells. MiR-339 inhibitor was capable of decreasing the miR-339 level to enhance the luciferase activities of the pGL3-Skp2-wt. It suggests that miR-339 can inhibit Skp2 expression through directly targeting its mRNA 3 0 UTR in lung cancer cells. In terms of function, miR-339 owned the ability by which miR-339 targets Skp2 to bate the cell proliferation in lung cancer in vitro. Our finding that miR-339 is capable of targeting the key oncoprotein, Skp2, provides new evidence for the tumor suppressor role of miR-339 in cancers.
For the first time, we present a novel role of miR-339 in post-transcriptional regulation of Skp2 for Skp2 inhibition, resulting in decreased cell proliferation in lung cancer. We gained novel insight into the mechanism of lung cancer growth induced by Skp2.
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